Drug Name:
EFUDEX CREAM Rx
Generic Name and Formulations:
Fluorouracil 5%.
Company:
Valeant Pharmaceuticals, Inc
Therapeutic Use:
Indications for EFUDEX CREAM:
Multiple actinic or solar keratoses. Superficial basal cell carcinoma when conventional therapy is impractical (5% only); see literature.
Adult:
Keratoses: Apply twice daily until erosion occurs (usually 2–4 wks). Basal cell carcinoma (5% only): Apply twice daily, usually for 3–6 weeks (obliteration may take 10–12 weeks).
Children:
Not recommended.
Contraindications:
Dihydropyrimidine dehydrogenase (DPD) deficiency. Pregnancy (Cat.X).
Warnings/Precautions:
Apply cautiously near eyes, nose, mouth. Avoid mucous membranes, occlusion, ulcerated/inflamed skin, exposure to UV light. Wash hands after application if fingers were used. Notify patients of expected skin reaction. Biopsy unresponsive lesions. Nursing mothers: not recommended.
See Also:
Pharmacological Class:
Antimetabolite.
Adverse Reactions:
Pain or burning at application site, pruritus, irritation, hyperpigmentation.
How Supplied:
Soln—10mL (w. drop dispenser); Crm—25g
Indications for EFUDEX CREAM:
Multiple actinic or solar keratoses. Superficial basal cell carcinoma when conventional therapy is impractical (5% only); see literature.
Adult:
Keratoses: Apply twice daily until erosion occurs (usually 2–4 wks). Basal cell carcinoma (5% only): Apply twice daily, usually for 3–6 weeks (obliteration may take 10–12 weeks).
Children:
Not recommended.
Contraindications:
Dihydropyrimidine dehydrogenase (DPD) deficiency. Pregnancy (Cat.X).
Warnings/Precautions:
Apply cautiously near eyes, nose, mouth. Avoid mucous membranes, occlusion, ulcerated/inflamed skin, exposure to UV light. Wash hands after application if fingers were used. Notify patients of expected skin reaction. Biopsy unresponsive lesions. Nursing mothers: not recommended.
See Also:
Pharmacological Class:
Antimetabolite.
Adverse Reactions:
Pain or burning at application site, pruritus, irritation, hyperpigmentation.
How Supplied:
Soln—10mL (w. drop dispenser); Crm—25g
Sign Up for Free e-newsletters
ONA Articles
- Real World Results May Not Mirror Clinical Study Outcomes in Multiple Myeloma
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Adding Bevacizumab to First-line Chemotherapy Benefits Selects Cases of Ovarian Cancer
- Assessing Direct Costs of Treatment-Related Adverse Events in Advanced Melanoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Health Domains May Mediate Psychological Risk in Survivors of Childhood Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |